Journals / İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2018 / Cilt: 22 - Sayı: 4

GLUCAGON LIKE PEPTID-1 (GLP-1) LEVELS IN INFLAMMATION OF PSORIATIC ARTHRITIS

PSÖRİYATİK ARTRİTTEKİ İNFLAMASYONDA GLUKAGON BENZERİ PEPTİD-1 (GLP-1) DÜZEYİ

Pages
131–136
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results of this study suggests that there is no significant relationship between GLP-1 and inflammatory process in patients with PsA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: In this study, we aimed to investigate the GLP-1 levels and its relationship with inflammation in patients with PsA.
📊
Key Findings & Data:Material and Method: Fasting blood GLP-1 levels were measured in PsA patients by using ELISA method and compared with those measured in the controls.
💡
Conclusion & Impact:Conclusion: The results of this study suggests that there is no significant relationship between GLP-1 and inflammatory process in patients with PsA.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: In this study, we aimed to investigate the GLP-1 levels and its relationship with inflammation in patients with PsA. Material and Method: Fasting blood GLP-1 levels were measured in PsA patients by using ELISA method and compared with those measured in the controls. We evaluated the GLP-1 levels and its relationship with disease activity in patients with PsA. Results: There was no statistically significant difference in the GLP-1 levels between PsA patients and healthy controls. No difference was determined in GLP-1 levels between patients with predominantly axial and predominantly peripheral disease and healthy controls. GLP-1 levels in patients with psoriasis and PsA were not correlated with the other disease activity scores. There was also no correlation between GLP-1 level and functional disease index and also health assessment parameters. The subgroup analysis in patients who were taking and not taking glucocorticoid treatment groups, revealed the similar results. Conclusion: The results of this study suggests that there is no significant relationship between GLP-1 and inflammatory process in patients with PsA.

Özet

Amaç: Çalışmanın amacı; psöriyatik artritteki inflamasyon ile GLP-1 düzeyleri arasında ilişki olup olmadığının araştırılmasıdır. Gereç ve Yöntem: Diyabetik olmayan psöriyatik artritli hasta ve sağlıklı kontrol grubunda, açlık kan GLP-1 düzeyleri ELISA yöntemiyle ölçülüp karşılaştırıldı. Psöriyatik artritli hastalarda GLP-1 düzeyleri ile hastalık aktivitesi arasında ilişki olup olmadığı değerlendirildi. Bulgular: Çalışma sonucunda; PsA’li hastalar ile sağlıklı grup arasındaki bazal GLP-1 düzeylerinde anlamlı bir fark olmadığı görüldü. Periferik veya aksiyel tutulumu ön planda olan hastalar arasında da GLP-1 düzeyleri farklı değildi. Bazal GLP-1 düzeylerinde, psöriyazis ve PsA olan grupta hastalık aktivite skorlarında istatistiksel olarak anlamlı bir faklılık saptanmadı. Yine bazal GLP-1 düzeyleri ile fonksiyonel hastalık indeksi, sağlık uygulama anketleri arasında korelasyon saptanmadı. Subgrup analizi yapıldığında; glukokortikoid alan ve almayan hastalar arasında da GLP-1 düzeylerinin farklı olmadığı görüldü. Sonuç: Çalışmamızın sonuçları PsA’deki inflamasyon ile GLP-1 arasında bir ilişki olmadığını düşündürmektedir.

🔖

Cite This Article

KESER, M., ÇETİN, P., SOLMAZ, D., KOZACI, L. D., KESER, A., ÖNEN, F. (2018). GLUCAGON LIKE PEPTID-1 (GLP-1) LEVELS IN INFLAMMATION OF PSORIATIC ARTHRITIS. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 22 - Sayı: 4, 131–136. https://ajindex.com/articles/198461

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Ogdie A, Langan S, Love T, Haynes K, Shin D, Seminara N, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford) 2013; 52(3): 568-75. Gladman DD. Axial disease in psoriatic arthritis. Curr Rheumatol Rep 2007; 9(6): 455-60.
  2. Armesto S, Santos-Juanes J, Galache-Osuna C, Martinez-Camblor P, Coto E, Coto-Segura P. Psoriasis and type 2 diabetes risk among psoriatic patients in a Spanish population. Australas J Dermatol 2012; 53(2): 128-30.
  3. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta- analysis. JAMA Dermatol 2013; 149(1): 84-91.
  4. Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol 2012; 148(9): 995-1000.
  5. Schwandt A, Bergis D, Dapp A, Ebner S, Jehle PM, Koppen S, et al. Psoriasis and Diabetes: A Multicenter Study in 222078 Type 2 Diabetes Patients Reveals High Levels of Depression. J Diabetes Res 2015; 2015: 792968. Al-Badri MR, Azar ST. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab 2014; 5(2): 34-8. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors. Diabetes Obes Metab 2016; 18(3): 203-16.
  6. Lynch M, Ahern TB, Timoney I, Sweeney C, Kelly G, Hughes R, et al. Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial. Trials 2016; 17: 29. Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol 2013; 27(11): 1440-3.
  7. Faurschou A, Knop FK, Thyssen JP, Zachariae C, Skov L, Vilsboll T. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol 2014; 51(1): 147-50.
  8. Faurschou A, Zachariae C, Skov L, Vilsboll T, Knop FK. Gastric bypass surgery: improving psoriasis through a GLP-1- dependent mechanism? Med Hypotheses 2011; 77(6): 1098-101.
  9. Congi L, Roussou E. Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol 2010; 28(3): 304-10.
  10. Shapiro J, Cohen AD, David M, H